2024 Vistagen therapeutics stock - Nov 9, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...

 
Dec 1, 2023 · Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ... . Vistagen therapeutics stock

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders.The stock appears to be pulling back after soaring more than 675% on Monday . What Happened: VistaGen shares surged Monday after the company said its Phase 3 PALISADE-2 trial of fasedienol nasal ...Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval. Subsidiaries VistaGen Therapeutics, Inc., a California corporation d/b/a VistaStem (VistaStem), is our wholly owned subsidiary. For the relevant periods, our Consolidated Financial Statements in this Quarterly Report on Form 10-Q (Report) ... Stock-based compensation expense for the quarter ended December 31, ...Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ...VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.Founded Date 1998. Founders H. Ralph Snodgrass. Operating Status Active. Last Funding Type Post-IPO Equity. Stock Symbol NASDAQ:VTGN. Company Type For Profit. Contact Email [email protected]. Phone Number 6505589566. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to …According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol. What this means: InvestorsObserver gives Vistagen Therapeutics Inc. (VTGN) an overall rank of 48, which is below average. Vistagen Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 48 means that 52% of stocks appear more favorable to our system.Vistagen is requesting approval from its stockholders to have the option to implement a Reverse Split if it becomes necessary to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq and maintain its Nasdaq listing.William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...Analyst Recommendations on Vistagen Therapeutics, Inc. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. 2022. MT. William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform. 2022.VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.VistaGen Therapeutics (VTGN) stock price prediction is 4.1154543085612 USD. The VistaGen Therapeutics stock forecast is 4.1154543085612 USD for 2024 ...Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into ... Aug 14, 2023 · Vistagen to Present at Stifel 2023 Healthcare Conference Nov 08, 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders ... Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or MDMA.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Dec 1, 2023 · Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ... VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Vistagen Therapeutics Inc ( VTGN) is up 6.73% today. VTGN has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.12 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between …fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval.Product Pipeline Chart. Our CNS pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines, in addition to AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Each of our drug candidates has a differentiated potential ...Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ... Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 59% ...Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst markets.businessinsider.com - November 14 at 6:25 PM: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript finance.yahoo.com - November 11 at 5:51 PMNov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Dec 1, 2023 · The VistaGen Therapeutics Inc stock price gained 1.67% on the last trading day (Friday, 1st Dec 2023), rising from $3.59 to $3.65. During the last trading day the stock fluctuated 6.05% from a day low at $3.47 to a day high of $3.68. The price has risen in 6 of the last 10 days and is up by 9.94% over the past 2 weeks. Find the latest Earnings Report Date for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade …Vistagen to Present at Stifel 2023 Healthcare Conference. SOUTH SAN FRANCISCO, Calif., November 08, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage …Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results.The pharmaceutical producer has been struggling all year, dipping into penny ...Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.1.34. +0.02. +1.52%. Get Vistagen Therapeutics Inc (VTGN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Dec 21, 2022 · Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ... VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ...Stifel Nicolaus initiated coverage on shares of Vistagen Therapeutics ( NASDAQ:VTGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm issued a buy rating and a $12.00 price target on the stock. Separately, Maxim Group reiterated a buy rating and issued a $30.00 price target on shares of …Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders. Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.5 hours ago · William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ... VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.Mental Health America’s prestigious national certification complements Vistagen’s ongoing efforts to improve mental health care across the U.S. Timely recognition comes during Mental Health...Get a real-time VistaGen Therapeutics, Inc. (VTGN) stock price quote with breaking news, financials, statistics, charts and more.Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical …Find the latest Vistagen Therapeutics, Inc. (VTGN) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report), with a price target of $12.00. Jason McCarthy’s Buy ...Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ...Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Vistagen to Present at Stifel 2023 Healthcare Conference Nov 08, 2023 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 8, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common ...Vistagen Therapeutics, Inc. Stock price Equities VTGN US92840H4002 Biotechnology & Medical Research Market Closed - Nasdaq. Other stock markets. …SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call …What this means: InvestorsObserver gives Vistagen Therapeutics Inc. (VTGN) an overall rank of 48, which is below average. Vistagen Therapeutics Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 48 means that 52% of stocks appear more favorable to our system.On August 10, VistaGen Therapeutics will report earnings from Q1. Analysts predict losses per share of $0.860. Watch VistaGen Therapeutics stock price move in real-time ahead here.According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therapeutic counseling ultimately seeks to show clients how their t...Dec 21, 2022 · Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ... Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the …VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.Jul 18, 2023 · Vistagen Therapeutics. VTGN. $2.57-0.32 (-11.07%) Share Price. as of November 10 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. More on Forbes. ... therapies and ... Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval. This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.Get the latest information on VistaGen Therapeutics Inc (VTGN), a biotechnology company developing gene therapies for neurological disorders. See the stock price, quote, chart, …Compare stocks to their industry peers at U.S. News Best Stocks. Money. Credit Cards. Best Of. ... VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ...fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval. Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022. …According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...Dec 21, 2022 · Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ... This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.Vistagen Therapeutics, Inc. 3.6500 +0.0600 +1.67%: TRENDING. 1. ... As U.S. stocks sit on hefty gains at the close of a rollercoaster year, investors are eyeing factors that could sway equities in ...Nov 9, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ... Every investor in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 59% ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700Vistagen therapeutics stock

Vistagen Therapeutics, Inc. (VTGN) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » VTGN Vistagen Therapeutics, Inc. …. Vistagen therapeutics stock

vistagen therapeutics stock

Maxim Group analyst Jason McCarthy maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report) yesterday and set a price target of $30.00.The company’s shares closed today at $6. ...Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing.Vistagen is requesting approval from its stockholders to have the option to implement a Reverse Split if it becomes necessary to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq and maintain its Nasdaq listing.Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) ... Common stock, $0.001 par value; 325,000,000 shares authorized at March 31, 2023 and March 31 ...Press Releases. Year. All Years. Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results. Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific …VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript. Get the latest Vistagen Therapeutics, Inc. (VTGN) stock news and headlines to help you in your trading and investing ...Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Vistagen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. To that end, Vistagen is developing an innovative pipeline of CNS medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of ...VistaGen Therapeutics has raised a total of. $154.8M. in funding over 8 rounds. Their latest funding was raised on Oct 2, 2023 from a Post-IPO Equity round. VistaGen Therapeutics is registered under the ticker NASDAQ:VTGN . VistaGen Therapeutics is funded by 9 investors. BVF Partners and TCG Crossover are the most recent investors.fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to …Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Advertisement Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After... Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results 8 days ago AMENDMENT NO. 4 CONSULTING SERVICES AGREEMENT 8 days ago VISTAGEN THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT 10-26 VISTAGEN THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO …VistaGen Therapeutics Stock Prediction 2030. In 2030, the VistaGen Therapeutics stock will reach $ 228.74 if it maintains its current 10-year average growth rate. If this VistaGen Therapeutics stock prediction for 2030 materializes, VTGN stock willgrow 6,271.71% from its current price.Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment …See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Feb 7, 2023 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.05 per share a year ago. Feb 7, 2023 · Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022. Jun 6, 2023 · SOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ... Find the latest news headlines from VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.Find the latest Earnings Report Date for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ...The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023.The analyst firm set a price target for $30.00 expecting VTGN to rise to within ...Jul 18, 2023 · Vistagen Therapeutics. VTGN. $2.57-0.32 (-11.07%) Share Price. as of November 10 4:00:00 PM EST. Vistagen Therapeutics (VTGN) Stock Price Performance. More on Forbes. ... therapies and ... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.Mar 25, 2020 · Going forward, subject to the terms and conditions of the agreement, VistaGen will have the option, but not any obligation, to sell to LPC up to an additional $10.0 million of its common stock over the next 24 months. VistaGen plans to use proceeds from the initial sale of common stock and subsequent sales under the agreement, if any, for ... Vistagen Therapeutics Inc (VTGN) stock is trading at $4.13 as of 9:52 AM on Monday, Oct 2, a drop of -$1.11, or -21.18% from the previous closing price of $5.24. The stock has traded between $4.00 and $4.89 so far today. Volume today is light. So far 312,282 shares have traded compared to average volume of 537,046 shares.SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ...With FDA feedback confirming the acceptable use of the LSAS as a primary efficacy endpoint, Vistagen is positioned to finalize key components of its potential New Drug Application (NDA)-enabling development program for fasedienol for treatment of SAD. Dr. Michael R. Liebowitz, a Columbia University psychiatrist, former director and founder …Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ...William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...Sep 29, 2023 · Learn more about whether Vistagen Therapeutics Inc is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how grades on certain investment factors and determine whether it meets your investment needs. Latest Vistagen Therapeutics Inc Stock News Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the …fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval.Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued. "Phase 3 topline results due in 2H 2023." This is one of three upcoming announcements for the company. VistaGen Therapeutics inched up $0.0018 (+1.29%) to $0.14 ...Compare stocks to their industry peers at U.S. News Best Stocks. Money. Credit Cards. Best Of. ... VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in ...VistaGen Therapeutics Inc stock price live 3.650, this page displays NASDAQ VTGN stock exchange data. View the VTGN premarket stock price ahead of the market session or assess the after hours quote.There are 137 funds or institutions reporting positions in VistaGen Therapeutics. This is a decrease of 34 owner (s) or 19.88% in the last quarter. Average portfolio weight of all funds dedicated ...Find the latest SEC Filings data for VistaGen Therapeutics, Inc. Common Stock (VTGN) at Nasdaq.com.About VTGN. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.Vistagen Therapeutics, Inc. 3.7200 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Stifel Nicolaus initiated coverage on shares of Vistagen Therapeutics ( NASDAQ:VTGN – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm issued a buy rating and a $12.00 price target on the stock. Separately, Maxim Group reiterated a buy rating and issued a $30.00 price target on shares of …VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.Oct 28, 2022 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 6, 2023-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common ... VistaGen Therapeutics Stock Earnings. The value each VTGN share was expected to gain vs. the value that each VTGN share actually gained. VistaGen Therapeutics ( VTGN) reported Q3 2023 earnings per share (EPS) of -$0.66, beating estimates of -$0.68 by 3.53%. In the same quarter last year, VistaGen Therapeutics 's earnings per share (EPS) was …Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment …Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Vistagen Therapeutics Inc ( VTGN) is up 0.89% today. VTGN has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.37 and is up $0.03 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ...Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Dec 1, 2023 · VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss SA News Fri, Aug. 12, 2022 2 Comments VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M ... Get the latest information on VistaGen Therapeutics Inc (VTGN), a biotechnology company developing gene therapies for neurological disorders. See the stock price, quote, chart, …The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ...Jun 6, 2023 · SOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ... SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ...Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued. Nov 6, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ... In a week that has seen Vistagen Therapeutics' stock triple in value, investors and company watchers have been intensely focused on the company. The fervor was in response to the positive Phase 3 ...VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ...Source Headline; Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week finance.yahoo.com - November 29 at 8:15 AM: Vistagen climbs as Stifel launches at Buy on anxiety prospects msn.com - November 14 at 6:25 PM: Anxiety-Focused Stock …VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...33. Shawn Singh. https://www.vistagen.com. Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates ...The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.Dec 6, 2022 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...Nov 15, 2022 · The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ... Get the latest Vistagen Therapeutics Inc (VTGN) stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's financial performance, balance sheet, cash flow, and market outlook for the first quarter of 2024. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. VistaGen Therapeutics Inc 50-day moving average is $3.73.Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.The second half of 2022 was always going to be a high-stakes moment for VistaGen Therapeutics as it awaited data from two phase 3 trials for a social anxiety disorder nasal spray.Vistagen is requesting approval from its stockholders to have the option to implement a Reverse Split if it becomes necessary to increase the per share price and bid price of the Company’s common stock in order to regain compliance with the $1.00 minimum bid price requirement of Nasdaq and maintain its Nasdaq listing.. Auto trading brokers